Sino Biological,Inc.

SZSE:301047 Stock Report

Market Cap: CN¥7.7b

Sino BiologicalInc Past Earnings Performance

Past criteria checks 1/6

Sino BiologicalInc's earnings have been declining at an average annual rate of -35.1%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 18.6% per year. Sino BiologicalInc's return on equity is 2.7%, and it has net margins of 24.3%.

Key information

-35.1%

Earnings growth rate

-45.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-18.6%
Return on equity2.7%
Net Margin24.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Sino BiologicalInc's (SZSE:301047) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 04
Sino BiologicalInc's (SZSE:301047) Shareholders Have More To Worry About Than Only Soft Earnings

Beyond Lackluster Earnings: Potential Concerns For Sino BiologicalInc's (SZSE:301047) Shareholders

May 06
Beyond Lackluster Earnings: Potential Concerns For Sino BiologicalInc's (SZSE:301047) Shareholders

Recent updates

Sino BiologicalInc's (SZSE:301047) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 04
Sino BiologicalInc's (SZSE:301047) Shareholders Have More To Worry About Than Only Soft Earnings

Sino Biological,Inc.'s (SZSE:301047) Shares Climb 31% But Its Business Is Yet to Catch Up

Sep 30
Sino Biological,Inc.'s (SZSE:301047) Shares Climb 31% But Its Business Is Yet to Catch Up

Sino BiologicalInc (SZSE:301047) Is Paying Out A Dividend Of CN¥2.00

May 21
Sino BiologicalInc (SZSE:301047) Is Paying Out A Dividend Of CN¥2.00

Sino Biological,Inc.'s (SZSE:301047) P/E Is Still On The Mark Following 26% Share Price Bounce

May 08
Sino Biological,Inc.'s (SZSE:301047) P/E Is Still On The Mark Following 26% Share Price Bounce

Beyond Lackluster Earnings: Potential Concerns For Sino BiologicalInc's (SZSE:301047) Shareholders

May 06
Beyond Lackluster Earnings: Potential Concerns For Sino BiologicalInc's (SZSE:301047) Shareholders

Revenue & Expenses Breakdown

How Sino BiologicalInc makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:301047 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2463515431893
30 Jun 2466019530691
31 Mar 2464222030488
31 Dec 2364626029187
30 Sep 2362023226182
30 Jun 2356824625073
31 Mar 2355627222373
01 Jan 2357530320860
30 Sep 2258344019347
30 Jun 2263047017345
31 Mar 2268550215743
01 Jan 2296572014640
30 Sep 211,34193313940
30 Jun 211,7361,23614333
31 Mar 211,9421,39616228
31 Dec 201,5961,12815125
31 Dec 19181368823
31 Dec 18139365722
31 Dec 17101134121

Quality Earnings: 301047 has high quality earnings.

Growing Profit Margin: 301047's current net profit margins (24.3%) are lower than last year (37.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 301047's earnings have declined by 35.1% per year over the past 5 years.

Accelerating Growth: 301047's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301047 had negative earnings growth (-33.6%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 301047's Return on Equity (2.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 05:07
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sino Biological,Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaying FuChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Kai WangCitic Securities Co., Ltd.